TFX Quote, Financials, Valuation and Earnings

Integra Lifesciences Holdings has a net margin of 13.56% compared to Teleflex's net margin of -6.61%. Teleflex's return on equity of 3.41% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Teleflex has a consensus price target of $157.62, signalling upside risk potential of 30.5%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 31.1%. Given that Integra Lifesciences Holdings has higher upside potential than Teleflex, analysts believe Integra Lifesciences Holdings is more attractive than Teleflex.

Teleflex has a beta of 1.170, which suggesting that the stock is 17.034% more volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.765%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.13%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $700.7M, which are larger than Integra Lifesciences Holdings quarterly revenues of $382.7M. Teleflex's net income of $95M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Teleflex's price-to-earnings ratio is 38.10x while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 1.87x versus 0.58x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 13.56% compared to Teleflex's net margin of 30.99%. Teleflex's return on equity of 3.41% beat Intuitive Surgical's return on equity of 15.82%.

Teleflex has a consensus price target of $157.62, signalling upside risk potential of 30.5%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 6.72%. Given that Teleflex has higher upside potential than Intuitive Surgical, analysts believe Teleflex is more attractive than Intuitive Surgical.

Teleflex has a beta of 1.170, which suggesting that the stock is 17.034% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.13%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teleflex pays 91.2% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $700.7M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Teleflex's net income of $95M is lower than Intuitive Surgical's net income of $698.4M. Notably, Teleflex's price-to-earnings ratio is 38.10x while Intuitive Surgical's PE ratio is 79.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 1.87x versus 22.47x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular has a net margin of 13.56% compared to Teleflex's net margin of 18.39%. Teleflex's return on equity of 3.41% beat LeMaitre Vascular's return on equity of 13.74%.

Teleflex has a consensus price target of $157.62, signalling upside risk potential of 30.5%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 28.38%. Given that Teleflex has higher upside potential than LeMaitre Vascular, analysts believe Teleflex is more attractive than LeMaitre Vascular.

Teleflex has a beta of 1.170, which suggesting that the stock is 17.034% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.076%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.13%. LeMaitre Vascular offers a yield of 0.89% to investors and pays a quarterly dividend of $0.20 per share. Teleflex pays 91.2% of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $700.7M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. Teleflex's net income of $95M is higher than LeMaitre Vascular's net income of $11M. Notably, Teleflex's price-to-earnings ratio is 38.10x while LeMaitre Vascular's PE ratio is 41.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 1.87x versus 8.22x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 13.56% compared to Teleflex's net margin of 28.26%. Teleflex's return on equity of 3.41% beat ResMed's return on equity of 25.76%.

Teleflex has a consensus price target of $157.62, signalling upside risk potential of 30.5%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 8.92%. Given that Teleflex has higher upside potential than ResMed, analysts believe Teleflex is more attractive than ResMed.

Teleflex has a beta of 1.170, which suggesting that the stock is 17.034% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Teleflex has a quarterly dividend of $0.34 per share corresponding to a yield of 1.13%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Teleflex pays 91.2% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Teleflex quarterly revenues are $700.7M, which are smaller than ResMed quarterly revenues of $1.3B. Teleflex's net income of $95M is lower than ResMed's net income of $365M. Notably, Teleflex's price-to-earnings ratio is 38.10x while ResMed's PE ratio is 27.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teleflex is 1.87x versus 7.13x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.